Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 14;4(4):FSO288.
doi: 10.4155/fsoa-2017-0133. eCollection 2018 Apr.

Granulocyte-macrophage colony-stimulating factor negatively regulates early IL-10-mediated responses

Affiliations

Granulocyte-macrophage colony-stimulating factor negatively regulates early IL-10-mediated responses

Ruud Hp Wilbers et al. Future Sci OA. .

Abstract

Aim: Treatment of inflammatory disorders relies on the intervention in immune responses thereby restoring homeostasis. IL-10 is a cytokine with therapeutic potential, but until now has not been as successful as previously anticipated. A reason for this may be that IL-10 responsiveness depends on the environment of the inflamed tissue. In this study we investigated whether GM-CSF is able to influence IL-10-mediated responses.

Methodology: Dendritic cells and macrophages were differentiated from mouse bone marrow and treated or depleted from GM-CSF prior to analyze their response to IL-10. Activity was assessed by measuring cytokine expression upon lipopolysaccharide stimulation, IL-10-induced signaling and down-stream gene expression.

Conclusion: This study describes that GM-CSF negatively regulates IL-10-mediated responses.

Keywords: dendritic cells; granulocyte-macrophage colony-stimulating factor (GM-CSF); interleukin-10 (IL-10); macrophages; signal transduction.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure This work was partly funded by Synthon BV, Nijmegen, The Netherlands. There was no additional external funding received for this study. Synthon BV supported this project financially but never interfered in the research approach. Furthermore, no patents or commercial products are under development based on this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. IL-10-mediated signaling in dendritic cells and macrophages.
(A) Macrophages and dendritic cells were pretreated with IL-10 and were stimulated with 100 ng/ml lipopolysaccharide and the inhibition of tumor necrosis factor-α expression was determined at 2 and 24 h (n = 3, error bars represent standard error). (B) Phosphorylation of tyrosine 705 (Y705) and serine 727 (S727) of STAT3 by IL-10 (0, 1, 10 and 100 ng/ml) were analyzed in macrophages and dendritic cells using western blot. (C & D) Relative induction of STAT3 phosphorylation was quantified for Y705 (C) and S727 (D) upon western-blot analysis (n = 3 or 4 for Y705 and S727, respectively, error bars represent standard error). (E) Macrophages and dendritic cells were treated with 100 ng/ml IL-10 and the activation of intracellular signaling pathways was analyzed with a PathScan Array. A representative figure is given for two independent experiments. Asterisk(s) indicate significant differences as determined by a Welch's t-test (*p < 0.05; **p < 0.01).
<b>Figure 2.</b>
Figure 2.. GM-CSF suppresses early IL-10-mediated responses.
Macrophages (A–C) and dendritic cells (D–F) were cultured for the last 24 h in the presence or absence (±) of GM-CSF. Cells were pretreated for 20 min with IL-10 followed by stimulation with 100 ng/ml lipopolysaccharide. The inhibition of TNF-α expression was determined after 24 h of stimulation (A & D). Alternatively, cells were pre-treated for 20 min with 10 ng/ml IL-10 and then stimulated with 100 ng/ml lipopolysaccharide. The inhibition of TNF-α expression was determined after 2 h of stimulation (B & E). Absolute expression levels of TNF-α for the abovementioned experiments are also given (C & F). All bars represent the average of 3–5 biological replicates (n = 3–5, error bars indicate standard error) and asterisk(s) indicate significant differences as determined by a Welch's t-test (*p < 0.05; **p < 0.01).
<b>Figure 3.</b>
Figure 3.. GM-CSF negatively influences IL-10 activity without affecting STAT3 activation.
(A) Macrophages were treated for 24 h with GM-CSF or left untreated. Cells were then activated with IL-10 (0, 1, 10 and 100 ng/ml) and phosphorylation of tyrosine 705 (Y705) and serine 727 (S727) of STAT3 were analyzed by western blot. (B) Relative socs3 transcript levels were analyzed by quantitative PCR in both macrophages and dendritic cells that were treated overnight by GM-CSF or were left untreated (n = 3, error bars represent standard error). Fold induction of socs3 expression upon IL-10 treatment (100 ng/ml) was calculated using the 2ΔCt method using HPRT as a reference gene and is depicted above the bars in the graph (macrophages/dendritic cells). (C) Macrophages and dendritic cells were treated overnight with GM-CSF or left untreated. Cells were then stimulated with 100 ng/ml IL-10 and the activation of intracellular signaling pathways was analyzed by PathScan Array. A representative figure is given for two independent experiments. Asterisk(s) indicate significant differences as determined by a Welch's t-test (*p < 0.05; **p < 0.01).

References

    1. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy – review of a new approach. Pharmacol. Rev. 2003;55(2):241–269. - PubMed
    1. Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997;113(2):383–389. - PubMed
    1. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119(6):1461–1472. - PubMed
    1. Marlow GJ, Van Gent D, Ferguson LR. Why interleukin-10 supplementation does not work in Crohn's disease patients. World J. Gastroenterol. 2013;19(25):3931–3941. - PMC - PubMed
    1. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289(5483):1352–1355. - PubMed

LinkOut - more resources